` ATOS (Atossa Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ATOS
vs
S&P 500

Over the past 12 months, ATOS has underperformed S&P 500, delivering a return of -40% compared to the S&P 500's +16% growth.

Stocks Performance
ATOS vs S&P 500

Loading
ATOS
S&P 500
Add Stock

Performance Gap
ATOS vs S&P 500

Loading
ATOS
S&P 500
Difference
www.alphaspread.com

Performance By Year
ATOS vs S&P 500

Loading
ATOS
S&P 500
Add Stock

Competitors Performance
Atossa Therapeutics Inc vs Peers

S&P 500
ATOS
ABBV
CYTH
AMGN
GILD
Add Stock

Atossa Therapeutics Inc
Glance View

Market Cap
114.5m USD
Industry
Biotechnology

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 4 full-time employees. The company went IPO on 2012-11-08. The firm is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. The company is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.

ATOS Intrinsic Value
4.683 USD
Undervaluation 81%
Intrinsic Value
Price
Back to Top